SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 02/03/25
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral ArteriesBusiness Wire • 02/03/25
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 01/30/25
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)Zacks Investment Research • 01/14/25
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/03/25
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy SystemBusiness Wire • 10/30/24
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in DiameterBusiness Wire • 10/01/24
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 09/06/24
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a TurnaroundZacks Investment Research • 09/05/24
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 08/15/24
Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 EarningsZacks Investment Research • 07/31/24